We are live on ! Find out more
RARE icon

Ultragenyx Pharmaceutical
RARE

274 hedge funds and large institutions have $3.63B invested in Ultragenyx Pharmaceutical in 2024 Q2 according to their latest regulatory filings, with 47 funds opening new positions, 117 increasing their positions, 80 reducing their positions, and 40 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 3 → 6 (+3)

52% more call options, than puts

Call options by funds: $22.7M | Put options by funds: $15M

46% more repeat investments, than reductions

Existing positions increased: 117 | Existing positions reduced: 80

18% more first-time investments, than exits

New positions opened: 47 | Existing positions closed: 40

2% more funds holding

Funds holding: 269 → 274 (+5)

0.33% more ownership

Funds ownership: 97.06% → 97.4% (+0.33%)

3% less capital invested

Capital invested by funds: $3.73B → $3.63B (-$103M)

Holders
274
Holders Change
+5
Holders Change %
+1.86%
% of All Funds
3.96%
Holding in Top 10
6
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+100%
% of All Funds
0.09%
New
47
Increased
117
Reduced
80
Closed
40
Calls
$22.7M
Puts
$15M
Net Calls
+$7.77M
Net Calls Change
-$6.85M

Top Buyers

1
VPC
Vestal Point Capital
New York
+$72.2M
2
Sands Capital Management
Sands Capital Management
Virginia
+$63.8M
3
Millennium Management
Millennium Management
New York
+$48.8M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$46.1M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$41.6M

Top Sellers

1
RI
RTW Investments
New York
-$163M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$24.6M
3
Pictet Asset Management
Pictet Asset Management
Switzerland
-$20.5M
4
EAM
Eventide Asset Management
Massachusetts
-$16.8M
5
Mirae Asset Global Investments
Mirae Asset Global Investments
South Korea
-$9.75M
Name Holding Trade Value Shares
Change 		Change in
Stake
Nisa Investment Advisors
251
Nisa Investment Advisors
Missouri
$3.29K – – –
LC
252
Lindbrook Capital
California
$3.25K -$1.62K -38 -32%
VCM
253
Versant Capital Management
Arizona
$3.21K +$3.33K +78 New
WTC
254
WhitTier Trust Company
Nevada
$2.88K – – –
PTC
255
Private Trust Company
Ohio
$1.97K -$256 -6 -11%
GRP
256
Global Retirement Partners
California
$1.85K – – –
Jones Financial Companies
257
Jones Financial Companies
Missouri
$1.56K +$1.62K +38 New
CFB
258
Cullen/Frost Bankers
Texas
$1.48K +$1.54K +36 New
IAIM
259
International Assets Investment Management
Florida
$1.44K +$1.49K +35 New
S
260
Sachetta
Massachusetts
$1.43K – – –
PWMG
261
Private Wealth Management Group
New Jersey
$1.4K – – –
CTC
262
Central Trust Company
Missouri
$987 – – –
JWM
263
Janiczek Wealth Management
Colorado
$822 – – –
MPWT
264
MassMutual Private Wealth & Trust
Connecticut
$740 – – –
AF
265
Allworth Financial
California
$724 -$85 -2 -11%
LFG
266
Larson Financial Group
Missouri
$699 +$726 +17 New
IC
267
Innealta Capital
Texas
$617 +$640 +15 New
SRCM
268
Signature Resources Capital Management
California
$616 – – –
BIA
269
Bell Investment Advisors
California
$453 – – –
CJ
270
Caitlin John
Michigan
$206 +$213 +5 New
CFGS
271
Concourse Financial Group Securities
Alabama
$123 +$128 +3 New
MG
272
Mather Group
Illinois
$93 +$85 +2 New
MCM
273
MV Capital Management
Maryland
$83 +$43 +1 +100%
EAM
274
Eventide Asset Management
Massachusetts
– -$16.8M -359,000 Closed
DTC
275
Deep Track Capital
Connecticut
– -$7.83M -167,784 Closed
9 10
11
12 13

RARE Hedge Fund Activity: Q2 2024 in Review

274 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q2 2024, worth a combined $3.63B — down 2.8% from $3.73B a quarter earlier.

Buyers outnumbered sellers: 47 funds opened new RARE positions and 40 closed out — a net gain of 7 holders — while 117 added to existing stakes and 80 trimmed.

The largest buyer was Vestal Point Capital, adding an estimated $72.2M. The largest seller was RTW Investments, cutting an estimated $163M.

  • 274 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q2 2024, up from 269 in Q1 2024.
  • Funds reported $3.63B of Ultragenyx Pharmaceutical stock for Q2 2024, down 2.8% quarter-over-quarter.
  • 47 funds opened new Ultragenyx Pharmaceutical positions in Q2 2024 and 40 closed out, a net change of +7 holders.
  • The largest Ultragenyx Pharmaceutical buyer in Q2 2024 was Vestal Point Capital, an estimated $72.2M added.
  • The largest Ultragenyx Pharmaceutical seller in Q2 2024 was RTW Investments, an estimated $163M sold.

Based on aggregated 13F filings for Q2 2024.